Track topics on Twitter Track topics that are important to you
Sanofi will acquire Bioverativ (BIVV) for $105 per share. Bioverativ spun from Biogen (BIIB) on Feb. 1, 2017. BIVV has returned 129%. Spin-Offs are 5x more likely to be acquired. Spin-Offs outperform the general market. Both this spin BIVV and BIIB are great examples of this over performance.
Original Article: Biogen Spin-Off Bioverativ To Be AcquiredNEXT ARTICLE
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...